| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $31.4M | — | +27.6% |
| SG&A Expense | $8.2M | — | +1.3% |
| Operating Income | -$39.6M | — | -21.1% |
| Net Income | -$35.8M | — | -19.1% |
| EPS (Basic) | -$0.34 | — | +19.0% |
| EPS (Diluted) | -$0.34 | — | +19.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $56.4M | +23.5% | +14.3% |
| Current Assets | $290.2M | +0.6% | +37.3% |
| Total Assets | $436.8M | +6.8% | +79.8% |
| Current Liabilities | $17.8M | -13.0% | +0.9% |
| Total Liabilities | $21.2M | -13.5% | -8.3% |
| Stockholders' Equity | $415.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$32.4M | — | +0.3% |
| Capital Expenditures | $2K | — | -99.5% |
| Investing Cash Flow | -$18.0M | — | -180.1% |
| Financing Cash Flow | $61.1M | — | — |
| Free Cash Flow | -$32.4M | — | +1.5% |
| +89.1% |